vs
Side-by-side financial comparison of Amphastar Pharmaceuticals, Inc. (AMPH) and ONE Group Hospitality, Inc. (STKS). Click either name above to swap in a different company.
ONE Group Hospitality, Inc. is the larger business by last-quarter revenue ($207.0M vs $183.1M, roughly 1.1× Amphastar Pharmaceuticals, Inc.). Amphastar Pharmaceuticals, Inc. runs the higher net margin — 13.3% vs -3.1%, a 16.4% gap on every dollar of revenue. On growth, Amphastar Pharmaceuticals, Inc. posted the faster year-over-year revenue change (-1.8% vs -6.7%). Amphastar Pharmaceuticals, Inc. produced more free cash flow last quarter ($24.6M vs $-329.0K). Over the past eight quarters, ONE Group Hospitality, Inc.'s revenue compounded faster (56.1% CAGR vs 3.2%).
Amphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company. It was incorporated in May 2004 and primarily develops, manufactures, and sells inhalation and intranasal products.
Target Hospitality is a company that provides workforce lodging and other temporary, modular housing used for oil, gas and mining operations; large-scale events; and disaster relief. Target Hospitality is based in The Woodlands, Texas, and also has offices in Williston, North Dakota; Denver, Colorado; Calgary, Alberta.
AMPH vs STKS — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $183.1M | $207.0M |
| Net Profit | $24.4M | $-6.4M |
| Gross Margin | 46.8% | — |
| Operating Margin | 19.4% | 2.2% |
| Net Margin | 13.3% | -3.1% |
| Revenue YoY | -1.8% | -6.7% |
| Net Profit YoY | -35.7% | -531.8% |
| EPS (diluted) | $0.51 | $-0.50 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $183.1M | $207.0M | ||
| Q3 25 | $191.8M | $180.2M | ||
| Q2 25 | $174.4M | $207.4M | ||
| Q1 25 | $170.5M | $211.1M | ||
| Q4 24 | $186.5M | $221.9M | ||
| Q3 24 | $191.2M | $194.0M | ||
| Q2 24 | $182.4M | $172.5M | ||
| Q1 24 | $171.8M | $85.0M |
| Q4 25 | $24.4M | $-6.4M | ||
| Q3 25 | $17.4M | $-76.7M | ||
| Q2 25 | $31.0M | $-10.1M | ||
| Q1 25 | $25.3M | $975.0K | ||
| Q4 24 | $38.0M | $1.5M | ||
| Q3 24 | $40.4M | $-9.3M | ||
| Q2 24 | $37.9M | $-7.3M | ||
| Q1 24 | $43.2M | $-2.1M |
| Q4 25 | 46.8% | — | ||
| Q3 25 | 51.4% | — | ||
| Q2 25 | 49.6% | — | ||
| Q1 25 | 50.0% | — | ||
| Q4 24 | 46.5% | — | ||
| Q3 24 | 53.3% | — | ||
| Q2 24 | 52.2% | — | ||
| Q1 24 | 52.4% | — |
| Q4 25 | 19.4% | 2.2% | ||
| Q3 25 | 13.2% | -4.4% | ||
| Q2 25 | 24.2% | 0.3% | ||
| Q1 25 | 21.9% | 5.1% | ||
| Q4 24 | 24.2% | 5.5% | ||
| Q3 24 | 29.8% | -1.9% | ||
| Q2 24 | 30.3% | 0.6% | ||
| Q1 24 | 27.9% | -0.7% |
| Q4 25 | 13.3% | -3.1% | ||
| Q3 25 | 9.0% | -42.6% | ||
| Q2 25 | 17.8% | -4.9% | ||
| Q1 25 | 14.8% | 0.5% | ||
| Q4 24 | 20.4% | 0.7% | ||
| Q3 24 | 21.1% | -4.8% | ||
| Q2 24 | 20.8% | -4.3% | ||
| Q1 24 | 25.1% | -2.4% |
| Q4 25 | $0.51 | $-0.50 | ||
| Q3 25 | $0.37 | $-2.75 | ||
| Q2 25 | $0.64 | $-0.59 | ||
| Q1 25 | $0.51 | $-0.21 | ||
| Q4 24 | $0.74 | $-0.18 | ||
| Q3 24 | $0.78 | $-0.53 | ||
| Q2 24 | $0.73 | $-0.38 | ||
| Q1 24 | $0.81 | $-0.07 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $282.8M | $4.2M |
| Total DebtLower is stronger | $608.7M | $354.2M |
| Stockholders' EquityBook value | $788.8M | $-75.8M |
| Total Assets | $1.6B | $884.2M |
| Debt / EquityLower = less leverage | 0.77× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $282.8M | $4.2M | ||
| Q3 25 | $276.2M | $5.5M | ||
| Q2 25 | $231.8M | $4.7M | ||
| Q1 25 | $236.9M | $21.4M | ||
| Q4 24 | $221.6M | $27.6M | ||
| Q3 24 | $250.5M | $28.2M | ||
| Q2 24 | $217.8M | $32.2M | ||
| Q1 24 | $289.6M | $15.4M |
| Q4 25 | $608.7M | $354.2M | ||
| Q3 25 | $608.6M | $355.0M | ||
| Q2 25 | $607.7M | $347.4M | ||
| Q1 25 | $603.9M | $348.3M | ||
| Q4 24 | $601.6M | $348.3M | ||
| Q3 24 | $596.4M | $349.1M | ||
| Q2 24 | $586.9M | $350.0M | ||
| Q1 24 | $594.0M | $73.5M |
| Q4 25 | $788.8M | $-75.8M | ||
| Q3 25 | $776.7M | $-61.5M | ||
| Q2 25 | $757.5M | $23.0M | ||
| Q1 25 | $751.3M | $40.5M | ||
| Q4 24 | $732.3M | $45.9M | ||
| Q3 24 | $727.7M | $51.4M | ||
| Q2 24 | $713.3M | $68.1M | ||
| Q1 24 | $672.4M | $68.3M |
| Q4 25 | $1.6B | $884.2M | ||
| Q3 25 | $1.7B | $879.5M | ||
| Q2 25 | $1.6B | $935.7M | ||
| Q1 25 | $1.6B | $956.0M | ||
| Q4 24 | $1.6B | $960.1M | ||
| Q3 24 | $1.5B | $953.5M | ||
| Q2 24 | $1.5B | $945.9M | ||
| Q1 24 | $1.6B | $309.3M |
| Q4 25 | 0.77× | — | ||
| Q3 25 | 0.78× | — | ||
| Q2 25 | 0.80× | 15.07× | ||
| Q1 25 | 0.80× | 8.61× | ||
| Q4 24 | 0.82× | 7.59× | ||
| Q3 24 | 0.82× | 6.79× | ||
| Q2 24 | 0.82× | 5.14× | ||
| Q1 24 | 0.88× | 1.08× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $32.9M | $13.1M |
| Free Cash FlowOCF − Capex | $24.6M | $-329.0K |
| FCF MarginFCF / Revenue | 13.4% | -0.2% |
| Capex IntensityCapex / Revenue | 4.5% | 6.5% |
| Cash ConversionOCF / Net Profit | 1.35× | — |
| TTM Free Cash FlowTrailing 4 quarters | $121.2M | $-27.3M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $32.9M | $13.1M | ||
| Q3 25 | $52.6M | $5.9M | ||
| Q2 25 | $35.6M | $2.8M | ||
| Q1 25 | $35.1M | $8.5M | ||
| Q4 24 | $29.0M | $18.5M | ||
| Q3 24 | $60.0M | $19.1M | ||
| Q2 24 | $69.1M | $-3.8M | ||
| Q1 24 | $55.3M | $10.4M |
| Q4 25 | $24.6M | $-329.0K | ||
| Q3 25 | $47.2M | $-6.1M | ||
| Q2 25 | $25.0M | $-15.0M | ||
| Q1 25 | $24.4M | $-5.8M | ||
| Q4 24 | $16.6M | $733.0K | ||
| Q3 24 | $46.2M | $287.0K | ||
| Q2 24 | $63.1M | $-23.0M | ||
| Q1 24 | $46.5M | $-5.4M |
| Q4 25 | 13.4% | -0.2% | ||
| Q3 25 | 24.6% | -3.4% | ||
| Q2 25 | 14.3% | -7.2% | ||
| Q1 25 | 14.3% | -2.7% | ||
| Q4 24 | 8.9% | 0.3% | ||
| Q3 24 | 24.1% | 0.1% | ||
| Q2 24 | 34.6% | -13.3% | ||
| Q1 24 | 27.1% | -6.4% |
| Q4 25 | 4.5% | 6.5% | ||
| Q3 25 | 2.8% | 6.7% | ||
| Q2 25 | 6.1% | 8.6% | ||
| Q1 25 | 6.3% | 6.8% | ||
| Q4 24 | 6.7% | 8.0% | ||
| Q3 24 | 7.2% | 9.7% | ||
| Q2 24 | 3.3% | 11.1% | ||
| Q1 24 | 5.1% | 18.6% |
| Q4 25 | 1.35× | — | ||
| Q3 25 | 3.03× | — | ||
| Q2 25 | 1.15× | — | ||
| Q1 25 | 1.39× | 8.76× | ||
| Q4 24 | 0.76× | 12.54× | ||
| Q3 24 | 1.48× | — | ||
| Q2 24 | 1.82× | — | ||
| Q1 24 | 1.28× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
STKS
| Benihanas | $111.3M | 54% |
| Steakhouse Restaurant | $59.2M | 29% |
| Grill Concepts | $32.3M | 16% |
| Other | $4.2M | 2% |
